{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:58Z","timestamp":1790821558014,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40120-024-00599-5","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:02:06Z","timestamp":1715868126000},"page":"1117-1133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-3737","authenticated-orcid":false,"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-1924","authenticated-orcid":false,"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-6163","authenticated-orcid":false,"given":"Yuge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-5816","authenticated-orcid":false,"given":"Juanjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"5","key":"599_CR1","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/s1474-4422(10)70064-8","volume":"9","author":"N Koch-Henriksen","year":"2010","unstructured":"Koch-Henriksen N, S\u00f8rensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520\u201332. https:\/\/doi.org\/10.1016\/s1474-4422(10)70064-8.","journal-title":"Lancet Neurol"},{"issue":"17","key":"599_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/wnl.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388. https:\/\/doi.org\/10.1212\/wnl.0000000000005347.","journal-title":"Neurology"},{"issue":"1","key":"599_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ncl.2017.08.013","volume":"36","author":"A Giorgio","year":"2018","unstructured":"Giorgio A, De Stefano N. Effective utilization of MRI in the diagnosis and management of multiple sclerosis. Neurol Clin. 2018;36(1):27\u201334. https:\/\/doi.org\/10.1016\/j.ncl.2017.08.013.","journal-title":"Neurol Clin"},{"issue":"3","key":"599_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","volume":"71","author":"CJ Bevan","year":"2014","unstructured":"Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71(3):269\u201370. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5486.","journal-title":"JAMA Neurol"},{"issue":"2","key":"599_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0404.2010.01444.x","volume":"124","author":"R Gold","year":"2011","unstructured":"Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75\u201384. https:\/\/doi.org\/10.1111\/j.1600-0404.2010.01444.x.","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"599_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1177\/1352458512450354","volume":"18","author":"AE Miller","year":"2012","unstructured":"Miller AE, O\u2019Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase\u00a0III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012;18(11):1625\u201332. https:\/\/doi.org\/10.1177\/1352458512450354.","journal-title":"Mult Scler"},{"issue":"3","key":"599_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/s1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2014;13(3):247\u201356. https:\/\/doi.org\/10.1016\/s1474-4422(13)70308-9.","journal-title":"Lancet Neurol"},{"issue":"10","key":"599_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/s1474-4422(14)70191-7","volume":"13","author":"AE Miller","year":"2014","unstructured":"Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2014;13(10):977\u201386. https:\/\/doi.org\/10.1016\/s1474-4422(14)70191-7.","journal-title":"Lancet Neurol"},{"issue":"5","key":"599_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000390","volume":"4","author":"EW Radue","year":"2017","unstructured":"Radue EW, Sprenger T, Gaetano L, et al. Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e390. https:\/\/doi.org\/10.1212\/nxi.0000000000000390.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"599_CR10","doi-asserted-by":"publisher","first-page":"175628642311811","DOI":"10.1177\/17562864231181170","volume":"16","author":"B Bu","year":"2023","unstructured":"Bu B, Quan C, Li W, et al. The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis. Ther Adv Neurol Disord. 2023;16:17562864231181170. https:\/\/doi.org\/10.1177\/17562864231181170.","journal-title":"Ther Adv Neurol Disord"},{"key":"599_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103446","volume":"58","author":"R Zhou","year":"2022","unstructured":"Zhou R, Li H, Yang H, et al. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis. Mult Scler Relat Disord. 2022;58:103446. https:\/\/doi.org\/10.1016\/j.msard.2021.103446.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"599_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"BA Cree","year":"2016","unstructured":"Cree BA, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499\u2013510. https:\/\/doi.org\/10.1002\/ana.24747.","journal-title":"Ann Neurol"},{"issue":"5","key":"599_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653\u201366. https:\/\/doi.org\/10.1002\/ana.25463.","journal-title":"Ann Neurol"},{"issue":"9","key":"599_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568.","journal-title":"JAMA Neurol"},{"issue":"2","key":"599_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ene.12715","volume":"23","author":"V Planche","year":"2016","unstructured":"Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol. 2016;23(2):282\u20139. https:\/\/doi.org\/10.1111\/ene.12715.","journal-title":"Eur J Neurol"},{"issue":"10","key":"599_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/wnl.0000000000002441","volume":"86","author":"P O'Connor","year":"2016","unstructured":"O\u2019Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920\u201330. https:\/\/doi.org\/10.1212\/wnl.0000000000002441.","journal-title":"Neurology"},{"key":"599_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102438","volume":"46","author":"AE Miller","year":"2020","unstructured":"Miller AE, Olsson TP, Wolinsky JS, et al. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: results from the TOWER extension study. Mult Scler Relat Disord. 2020;46:102438. https:\/\/doi.org\/10.1016\/j.msard.2020.102438.","journal-title":"Mult Scler Relat Disord"},{"key":"599_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.msard.2019.05.014","volume":"33","author":"AE Miller","year":"2019","unstructured":"Miller AE, Vermersch P, Kappos L, et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: results of the TOPIC extension study. Mult Scler Relat Disord. 2019;33:131\u20138. https:\/\/doi.org\/10.1016\/j.msard.2019.05.014.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"599_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1756285617722500","volume":"10","author":"AE Miller","year":"2017","unstructured":"Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord. 2017;10(12):381\u201396. https:\/\/doi.org\/10.1177\/1756285617722500.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"599_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdov\u00e1 E. \u201cNo evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23(9):1179\u201387. https:\/\/doi.org\/10.1177\/1352458517703193.","journal-title":"Mult Scler"},{"issue":"9","key":"599_CR21","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1007\/s00415-022-11118-7","volume":"269","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study. J Neurol. 2022;269(9):4808\u201316. https:\/\/doi.org\/10.1007\/s00415-022-11118-7.","journal-title":"J Neurol"},{"issue":"5","key":"599_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/cer-2018-0135","volume":"8","author":"R Zivadinov","year":"2019","unstructured":"Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. J Comp Eff Res. 2019;8(5):305\u201316. https:\/\/doi.org\/10.2217\/cer-2018-0135.","journal-title":"J Comp Eff Res"},{"issue":"2","key":"599_CR23","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1007\/s00415-021-10455-3","volume":"268","author":"S Bucello","year":"2021","unstructured":"Bucello S, Annovazzi P, Ragonese P, et al. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. J Neurol. 2021;268(2):2922\u201332. https:\/\/doi.org\/10.1007\/s00415-021-10455-3.","journal-title":"J Neurol"},{"issue":"6","key":"599_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","volume":"263","author":"T Ziemssen","year":"2016","unstructured":"Ziemssen T, Derfuss T, De Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263(6):1053\u201365. https:\/\/doi.org\/10.1007\/s00415-015-7986-y.","journal-title":"J Neurol"},{"issue":"1","key":"599_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","volume":"23","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23(1):94\u2013105. https:\/\/doi.org\/10.1177\/1352458516638941.","journal-title":"Mult Scler"},{"issue":"11","key":"599_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1177\/13524585221089534","volume":"28","author":"T Sprenger","year":"2022","unstructured":"Sprenger T, Kappos L, Sormani MP, et al. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: post hoc analysis of the TEMSO core and extension studies. Mult Scler. 2022;28(11):1719\u201328. https:\/\/doi.org\/10.1177\/13524585221089534.","journal-title":"Mult Scler"},{"key":"599_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.msard.2017.07.006","volume":"17","author":"PK Coyle","year":"2017","unstructured":"Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107\u201315. https:\/\/doi.org\/10.1016\/j.msard.2017.07.006.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00599-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T18:19:46Z","timestamp":1721672386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00599-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00599-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Third Affiliated Hospital, Sun Yat-sen University (approval number [2007]33).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}